Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. OBJECTIVES: This study sought to identify protein biomarkers associated with HCM penetrance and severity. METHODS: Olink-assayed plasma proteins of 144 pathogenic MYBPC3 variant carriers were evaluated for associations with HCM severity based on diagnostic criteria (unaffected, mildly, or severely affected). Identified proteins were replicated in the UK Biobank considering time to onset of HCM (67 cases), cardiomyopathy (156 cases), and associations with left ventricular maximum wall thickness (6,492 participants). After prioritizing proteins on cardiac tissue expression and druggability, we examined disease penetrance through associations with heart failure (HF) and arrhythmic outcomes in 272 UK Biobank participants with known pathogenic HCM variants free of cardiomyopathy at proteomics assessment. RESULTS: Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity, of which 22 replicated in the UK Biobank. Six proteins were prioritized (N-terminal pro-B-type natriuretic peptide [NT-proBNP], growth/differentiation factor [GDF]-15, fibroblast growth factor [FGF]-23, adrenomedullin [ADM], renin [REN], and neural cell adhesion molecule 1 [NCAM1]), of which 5 associated with disease penetrance in pathogenic variant carriers: NT-proBNP and REN associated with increased HF and arrhythmic risk, GDF-15 and FGF-23 with HF risk, and NCAM1 with arrhythmic risk. CONCLUSIONS: Through the integration of proteomic analyses in both clinical and general population cohorts, we replicated and prioritized 6 proteins associated with HCM penetrance and severity. These findings highlight potential plasma-based markers for diagnosis and disease monitoring, as well as promising targets for future therapeutic development.

Authors

Institutions

Publication Details

Journal
JACC Advances
Published
2026-11-17
DOI
https://doi.org/10.1016/j.jacadv.2026.103457
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers

Karin Y. van Spaendonck‐Zwarts, Jolanda van der Velden, Connie R. Bezzina, Bram Ruijsink et al.
3 links
JACC Advances
Cardiomyopathy and Myosin Studies
article

Identifying Plasma Proteins for Hypertrophic Cardiomyopathy Penetrance and Severity in Pathogenic Variant Carriers and Noncarriers

Karin Y. van Spaendonck‐Zwarts, Jolanda van der Velden, Connie R. Bezzina, Bram Ruijsink, Amand Floriaan Schmidt, Annette F. Baas, Dennis Dooijes, Folkert Wouter Asselbergs, Ahmad S. Amin, Jan D.H. Jongbloed, Ronald H. Lekanne Deprez, Saskia N. van der Crabben, Diederik W.D. Kuster, J. Peter van Tintelen, Moniek G.P.J. Cox, Anneline S.J.M. te Riele, Fahima Hassanzada, M. Jansen, Marion van Vugt
article en

Abstract

BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a clinically variable disease in onset and progression. Pathogenic MYBPC3 variants account for a substantial proportion of HCM diagnoses. OBJECTIVES: This study sought to identify protein biomarkers associated with HCM penetrance and severity. METHODS: Olink-assayed plasma proteins of 144 pathogenic MYBPC3 variant carriers were evaluated for associations with HCM severity based on diagnostic criteria (unaffected, mildly, or severely affected). Identified proteins were replicated in the UK Biobank considering time to onset of HCM (67 cases), cardiomyopathy (156 cases), and associations with left ventricular maximum wall thickness (6,492 participants). After prioritizing proteins on cardiac tissue expression and druggability, we examined disease penetrance through associations with heart failure (HF) and arrhythmic outcomes in 272 UK Biobank participants with known pathogenic HCM variants free of cardiomyopathy at proteomics assessment. RESULTS: Among pathogenic MYBPC3 variant carriers, we identified 27 proteins associated with HCM severity, of which 22 replicated in the UK Biobank. Six proteins were prioritized (N-terminal pro-B-type natriuretic peptide [NT-proBNP], growth/differentiation factor [GDF]-15, fibroblast growth factor [FGF]-23, adrenomedullin [ADM], renin [REN], and neural cell adhesion molecule 1 [NCAM1]), of which 5 associated with disease penetrance in pathogenic variant carriers: NT-proBNP and REN associated with increased HF and arrhythmic risk, GDF-15 and FGF-23 with HF risk, and NCAM1 with arrhythmic risk. CONCLUSIONS: Through the integration of proteomic analyses in both clinical and general population cohorts, we replicated and prioritized 6 proteins associated with HCM penetrance and severity. These findings highlight potential plasma-based markers for diagnosis and disease monitoring, as well as promising targets for future therapeutic development.

JACC AdvancesVol. 5(12)
University Medical Center Groningen (NL), King's College London (GB), Utrecht University (NL), University Medical Center Utrecht (NL), British Heart Foundation (GB), Amsterdam Neuroscience (NL), UCL Biomedical Research Centre (GB), ERN GUARD-Heart (NL), Amsterdam University Medical Centers (NL), Amsterdam Cardiovascular Sciences (NL), University College London (GB), Vrije Universiteit Amsterdam (NL), University of Amsterdam (NL), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Bristol-Myers Squibb, Government of the United Kingdom, UK Research and Innovation, Dutch Cardiovascular Alliance, National Institute for Health and Care Research, British Heart Foundation, University College London, ZonMw, Nederlandse Organisatie voor Wetenschappelijk Onderzoek, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centers, UCLH Biomedical Research Centre, HORIZON EUROPE European Innovation Council
Good health and well-being
Cardiomyopathy and Myosin Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon